60 Degrees Pharmaceuticals (SXTP) Gross Profit (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Gross Profit of $76377.0 for Q1 2026, down 15.4% year-over-year from $90280.0 in Q1 2025, and down 58.2% quarter-over-quarter from $182703.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Gross Profit (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Gross Profit for 5 consecutive years, with $76377.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Profit fell 15.4% year-over-year to $76377.0; the TTM figure through Mar 2026 stood at $209873.0 (down 23.08% YoY), while the FY2025 annual figure was $223776.0, changed 0.43% from the prior year.
- Gross Profit declined to $76377.0 in Q1 2026 per SXTP's latest filing, from $182703.0 in the prior quarter.
- Across five years, Gross Profit topped out at $417493.0 in Q2 2022 and bottomed at -$162835.0 in Q4 2022.
- Historically, Gross Profit has averaged $39534.2 across 5 years, with a median of $37822.5 in 2024.
- Annual changes were most pronounced in 2024 — Gross Profit jumped 700.5% — and 2025, when it plunged 523.99%.
- 60 Degrees Pharmaceuticals' Gross Profit stood at -$162835.0 in 2022, then jumped by 87.36% to -$20576.0 in 2023, then jumped by 700.5% to $123558.0 in 2024, then soared by 47.87% to $182703.0 in 2025, then sank by 58.2% to $76377.0 in 2026.
- Business Quant data shows SXTP's Gross Profit at $76377.0 in Q1 2026, $182703.0 in Q4 2025, and -$100088.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76,377.00 |
| Mar 31, 2026 | 76,377.00 |
| Dec 31, 2025 | 182,703.00 |
| Dec 31, 2025 | 182,703.00 |
| Sep 30, 2025 | -100,088.00 |
| Sep 30, 2025 | -100,088.00 |
| Jun 30, 2025 | 50,881.00 |
| Jun 30, 2025 | 50,881.00 |
| Mar 31, 2025 | 90,280.00 |
| Mar 31, 2025 | 90,280.00 |
| Dec 31, 2024 | 123,558.00 |
| Dec 31, 2024 | 123,558.00 |
| Sep 30, 2024 | 23,606.00 |
| Sep 30, 2024 | 23,606.00 |
| Jun 30, 2024 | 35,408.00 |
| Jun 30, 2024 | 35,408.00 |
| Mar 31, 2024 | 40,237.00 |
| Mar 31, 2024 | 40,237.00 |
| Dec 31, 2023 | -20,576.00 |
| Dec 31, 2023 | -20,576.00 |